These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 29803076)

  • 1. Brush border enzyme-cleavable linkers: Evaluation for reducing renal uptake of radiolabeled prostate-specific membrane antigen inhibitors.
    Vaidyanathan G; Kang CM; McDougald D; Minn I; Brummet M; Pomper MG; Zalutsky MR
    Nucl Med Biol; 2018; 62-63():18-30. PubMed ID: 29803076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy.
    Kiess AP; Minn I; Vaidyanathan G; Hobbs RF; Josefsson A; Shen C; Brummet M; Chen Y; Choi J; Koumarianou E; Baidoo K; Brechbiel MW; Mease RC; Sgouros G; Zalutsky MR; Pomper MG
    J Nucl Med; 2016 Oct; 57(10):1569-1575. PubMed ID: 27230930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and preliminary evaluation of
    Vaidyanathan G; Mease RC; Minn I; Choi J; Chen Y; Shallal H; Kang CM; McDougald D; Kumar V; Pomper MG; Zalutsky MR
    Nucl Med Biol; 2021; 94-95():67-80. PubMed ID: 33601187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [(18)F]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance.
    Chen Y; Lisok A; Chatterjee S; Wharram B; Pullambhatla M; Wang Y; Sgouros G; Mease RC; Pomper MG
    Bioconjug Chem; 2016 Jul; 27(7):1655-62. PubMed ID: 27270097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.
    Chen Y; Pullambhatla M; Foss CA; Byun Y; Nimmagadda S; Senthamizhchelvan S; Sgouros G; Mease RC; Pomper MG
    Clin Cancer Res; 2011 Dec; 17(24):7645-53. PubMed ID: 22042970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PSMA-reactive NB7 single domain antibody fragment: A potential scaffold for developing prostate cancer theranostics.
    Huynh TT; Feng Y; Meshaw R; Zhao XG; Rosenfeld L; Vaidyanathan G; Papo N; Zalutsky MR
    Nucl Med Biol; 2024; 134-135():108913. PubMed ID: 38703588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor Uptake of Triazine Dendrimers Decorated with Four, Sixteen, and Sixty-Four PSMA-Targeted Ligands: Passive versus Active Tumor Targeting.
    Lim J; Guan B; Nham K; Hao G; Sun X; Simanek EE
    Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31466360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of
    Potemkin R; Strauch B; Kuwert T; Prante O; Maschauer S
    Mol Pharm; 2020 Mar; 17(3):933-943. PubMed ID: 32011889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What a difference a methylene makes: replacing Glu with Asp or Aad in the Lys-urea-Glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake.
    Kuo HT; Lin KS; Zhang Z; Zhang C; Merkens H; Tan R; Roxin A; Uribe CF; Bénard F
    Theranostics; 2022; 12(14):6179-6188. PubMed ID: 36168623
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Kuo HT; Lin KS; Zhang Z; Uribe CF; Merkens H; Zhang C; Bénard F
    J Nucl Med; 2021 Apr; 62(4):521-527. PubMed ID: 32859704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vitro and In Vivo Characterization of an
    Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S
    J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and evaluation of a novel urea-based
    Zha Z; Ploessl K; Choi SR; Wu Z; Zhu L; Kung HF
    Nucl Med Biol; 2018 Apr; 59():36-47. PubMed ID: 29459281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
    Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
    J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window.
    Kelly JM; Amor-Coarasa A; Ponnala S; Nikolopoulou A; Williams C; DiMagno SG; Babich JW
    J Nucl Med; 2019 May; 60(5):656-663. PubMed ID: 30552199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
    Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H
    J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Linker Modification on Tumor-to-Kidney Contrast of
    Kuo HT; Pan J; Zhang Z; Lau J; Merkens H; Zhang C; Colpo N; Lin KS; Bénard F
    Mol Pharm; 2018 Aug; 15(8):3502-3511. PubMed ID: 29920108
    [No Abstract]   [Full Text] [Related]  

  • 17. Synthesis and pre-clinical evaluation of a new class of high-affinity
    Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical Evaluation of a New Series of Albumin-Binding
    Boinapally S; Alati S; Jiang Z; Yan Y; Lisok A; Singh R; Lofland G; Minn I; Hobbs RF; Pomper MG; Banerjee SR
    Molecules; 2023 Aug; 28(16):. PubMed ID: 37630410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel technetium-99m-labeled bivalent PSMA-targeting probe based on hydroxamamide chelate for diagnosis of prostate cancer.
    Shimizu Y; Ando M; Watanabe H; Ono M
    Ann Nucl Med; 2024 Oct; 38(10):847-851. PubMed ID: 38976087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
    Umbricht CA; Benešová M; Schibli R; Müller C
    Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.